文章：

鞘脂在炎症性肠病与结直肠癌中的治疗潜力

Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer

原文发布日期：15 February 2024

DOI: 10.3390/cancers16040789

类型: Article

开放获取: 是

英文摘要：

Inflammatory bowel disease (IBD), characterized by chronic inflammation in the intestinal tract, increases the risk for the development of colorectal cancer (CRC). Sphingolipids, which have been implicated in IBD and CRC, are a class of bioactive lipids that regulate cell signaling, differentiation, apoptosis, inflammation, and survival. The balance between ceramide (Cer), the central sphingolipid involved in apoptosis and differentiation, and sphingosine-1-phosphate (S1P), a potent signaling molecule involved in proliferation and inflammation, is vital for the maintenance of normal cellular function. Altered sphingolipid metabolism has been implicated in IBD and CRC, with many studies highlighting the importance of S1P in inflammatory signaling and pro-survival pathways. A myriad of sphingolipid analogues, inhibitors, and modulators have been developed to target the sphingolipid metabolic pathway. In this review, the efficacy and therapeutic potential for modulation of sphingolipid metabolism in IBD and CRC will be discussed.

摘要翻译： 

炎症性肠病（IBD）以肠道慢性炎症为特征，会增加结直肠癌（CRC）的发病风险。鞘脂作为一类参与IBD与CRC过程的生物活性脂质，可调控细胞信号传导、分化、凋亡、炎症反应及存活。作为参与细胞凋亡与分化的核心鞘脂，神经酰胺（Cer）与作为参与增殖和炎症的关键信号分子——鞘氨醇-1-磷酸（S1P）之间的动态平衡，对维持正常细胞功能至关重要。大量研究证实鞘脂代谢紊乱与IBD及CRC的发生发展密切相关，其中S1P在炎症信号传导和促存活通路中的关键作用尤为突出。目前已有多种靶向鞘脂代谢通路的类似物、抑制剂及调节剂被研发。本综述将系统探讨调控鞘脂代谢在IBD与CRC治疗中的效能及临床应用前景。

原文链接：

Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer